Velcade Phase III Studies Will Support First-Line Use, Millennium Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to initiate three Phase III studies to support full approval of Velcade for treatment of multiple myeloma. FDA grants priority review designation to Velcade sNDA for second-line use, Millennium announces.